[Cutaneous presentation of plasmablastic lymphoma in a patient with HIV Infection].
Zaragoza
V
V
Martínez
L
L
Pérez-Ferriols
A
A
Alegre
V
V
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D007262:Infusions, Intravenous; D007278:Injections, Spinal; D016483:Lymphoma, AIDS-Related / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D015819:Substance Abuse, Intravenous / Q000150:complications; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D015703:Antigens, CD; D014408:Biomarkers, Tumor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone